Teva, Drugmakers in Talks With U.S. to End Generics Probes

Teva Pharmaceutical Industries and other generic drugmakers have held talks with the U.S. Justice Department in the past 6 months about resolving a long-running criminal antitrust probe of alleged price-fixing by the companies, according to people familiar with the matter, as reported by Bloomberg News.

Among the possible outcomes that have been discussed are deferred prosecution agreements in which the companies would admit to certain allegations but would be shielded from indictment in exchange for cooperating with the investigation and paying fines.

Read the full article.